Overview

Protein and lipid kinases stand in the center  spotlight of academic and industrial research. The launched drugs Gefitinib, Erlotinib, and Gleevec have already helped to save thousands of lives by inhibiting specific kinase leading to inhibition of cancer growth. Besides cancer the inhibition of kinases may be the key to treating other diseases, including neurological and autoimmune diseases. Over the last 18 years biannual IPK in Warsaw organized and later mentored by the late Prof. David Shugar brought together the top kinase international researchers from academia and industry. We plan to build on the success of the previous meetings and broaden the topics to include current trend in kinase inhibition. As we have done in the past, we assembled top researchers to serve as a magnet for growing the meeting even more.
Due to their critical role in cellular signaling, protein kinases have been one of the most popular target families for drug discovery. Since the determination of the atomic structure of the first human kinase more than 20 years ago, and the publication of the human kinome more than 10 years ago, a huge amount of research has been done to understand kinase biology and to find ways of targeting these enzymes to treat disease.
Over the last 18 years biannual IPK in Warsaw organized and later mentored by Prof. David Shugar brought together the top kinase international researchers from academia and industry. The conference featured first discoveries of novel kinase inhibitors (eg. BIRB-796 in 2001), kinase drug discovery stories (eg. Gleevec), innovative technologies (eg. ASKA kinase/Shokat), novel concepts (kinase spine, types of kinase inhibitors), breakthrough structural data (Knapp), featured Nobel prize laureates (Huber), popularized and broadened interest of kinase inhibitors in infective diseases (Christian Doerig), originated multiple collaborations and equally importantly served as education for hundreds of students and postdocs and researchers to develop their careers.
All eight previous conferences were featured in 8 special issues of journals(1-8) generating highly impactful series of 211 academic papers (listed in supplementary material) with over 12377 citations (source CALPLUS).  Multiple articles from the conference proceedings achieved citation classic status with most cited paper(9) having over 800 citations (Google Schoolar).  The high, documented impact of this meeting series to the kinase scientific community complements, and in many aspects exceeds other high impact academic meetings like FASEB Series and commercially oriented kinase meetings.
The conference series evolved in each iteration broadening the scope to current “hot topics” in contemporary kinase research, while retaining its roots in focus on the understanding of role of kinases in biology and disease through the use their inhibitors.  We plan to build on the success of the previous meetings and broaden the topics to include current trend in kinase inhibition through the use of antibodies and drug conjugates as well as bring current hot technologies to study biomoleucules in case studies involving kinases(EM). As we have done in the past, we will assemble an exciting list of top international academic and industrial researchers to serve as a magnet for growing the meeting even more.
The last day of the conference will be dedicated to the memory of Professor David Shugar (1915-2015), who should be regarded as the creator of the Polish school of molecular biophysics. He has coauthored over three hundred publications, cited ~8000 times. We are inviting not only his collaborators, majority of whose interest is strictly related to the various kinase projects, but also his scientific successors (mainly former students at Biophysics Department of University of Warsaw) diffused throughout the world. Three short oral presentations are tentatively reserved for remarkable young researchers active at Ochota Scientific Campus.
Our goal, as organizers, is to continue the conference series with a short term goal of organizing the meeting in September 2017, expanding the topics to broaden the interest and long term goal of creating a legacy of meetings that foster scientific, documented impactful interactions, industry-academic collaborations and contribute to the development of young scientists.

Comments are closed